INTESTINAL NEUROENDOCRINE CARCINOMA
Clinical trials for INTESTINAL NEUROENDOCRINE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new INTESTINAL NEUROENDOCRINE CARCINOMA trials appear
Sign up with your email to follow new studies for INTESTINAL NEUROENDOCRINE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …
Matched conditions: INTESTINAL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug combo tested against standard for rare, aggressive gut cancers
Disease control OngoingThis study is testing whether a newer chemotherapy combination (temozolomide and capecitabine) works better than the current standard treatment (cisplatin/carboplatin and etoposide) for patients with an advanced, fast-growing type of neuroendocrine cancer in the stomach, intestin…
Matched conditions: INTESTINAL NEUROENDOCRINE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC